Brady Stein, MD
Hematology · Chicago, ILNPI 1134275845
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,950 of the $6,060 with a category attached, or 98.2%. Bristol Myers Squibb accounts for 79.4% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $2019.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$5K
- Incyte Corporation$1K
Across 44 payments — averaging $11,563 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$255K
- Incyte Corporation$193K
- AbbVie$59K
- CTI Biopharma Corp.$2K
What the payments were for
- Consulting fees$5,95098%
- Food & beverage$1102%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 2 | $4,810 |
| Incyte Corporation | 1 | $1,250 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fedratinib$4,810
How this compares
$6,060 in reported general payments places this provider in the 65th percentile of 49 hematology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 154 | $2,341,938 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $326,567 |
| EliquisApixaban | 307 | $300,281 |
| BesremiRopeginterferon Alfa-2b-Njft | 27 | $223,001 |
| XareltoRivaroxaban | 162 | $174,770 |
| PromactaEltrombopag Olamine | 17 | $139,547 |
| Hydroxyurea | 386 | $7,890 |
| Deferasirox | 13 | $3,146 |
| Imatinib Mesylate | 18 | $653 |
| Penicillin V Potassium | 11 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $1,250 | $2,341,938154 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 hematology providers in Illinois.
Other hematology in Chicago
- Jayesh MehtaChicago$183K
- Celalettin UstunChicago$153K
- Kunal DesaiChicago$150K
- John QuigleyChicago$132K
- Parameswa VenugopalChicago$122K
- Nadia KhanChicago$66K
- Seema SinghalChicago$65K
- Olga FrankfurtChicago$49K
- Deborah KatzChicago$38K
- Martin TallmanChicago$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.